JO3524B1 - Injectable preparation - Google Patents
Injectable preparationInfo
- Publication number
- JO3524B1 JO3524B1 JOP/2013/0115A JOP20130115A JO3524B1 JO 3524 B1 JO3524 B1 JO 3524B1 JO P20130115 A JOP20130115 A JO P20130115A JO 3524 B1 JO3524 B1 JO 3524B1
- Authority
- JO
- Jordan
- Prior art keywords
- quinolin
- thiophen
- piperazin
- benzo
- butoxy
- Prior art date
Links
- 239000004480 active ingredient Substances 0.000 abstract 2
- ZKIAIYBUSXZPLP-UHFFFAOYSA-N brexpiprazole Chemical compound C1=C2NC(=O)C=CC2=CC=C1OCCCCN(CC1)CCN1C1=CC=CC2=C1C=CS2 ZKIAIYBUSXZPLP-UHFFFAOYSA-N 0.000 abstract 2
- MVMLSUJZHCVWAV-UHFFFAOYSA-N 1-[4-[4-(1-benzothiophen-4-yl)piperazin-1-yl]butoxy]quinolin-2-one Chemical compound O=C1C=CC2=CC=CC=C2N1OCCCCN(CC1)CCN1C1=CC=CC2=C1C=CS2 MVMLSUJZHCVWAV-UHFFFAOYSA-N 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000002035 prolonged effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 238000013268 sustained release Methods 0.000 abstract 1
- 239000012730 sustained-release form Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Dispersion Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
0An object of the present invention is to provide a sustained release injectable preparation which is in a medication administration from that can provide the effect of 7-[4-(4- benzo [b] thiophen-4-yl-piperazin-1-yl) butoxy]-1H-quinolin-2-one for a prolonged period of time, the preparation releasing a therapeutically effective amount of 7-[4-(4-benzo [b] thiophen-4-yl-piperazin-1-yl) butoxy]-1H-quinolin-2-one for at least one week. The present invention provides an injectable preparation containing 7-4[4-(4-benzo[b] thiophen-4-yl-piperazin-1-yl) butoxy]-1H-quinolin-2-one or a salt thereof as an active ingredient, which released the active ingredient in such manner that a therapeutically effective blood concentration thereof is maintained for at least 1 week.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261636932P | 2012-04-23 | 2012-04-23 | |
| US201361791896P | 2013-03-15 | 2013-03-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JO3524B1 true JO3524B1 (en) | 2020-07-05 |
Family
ID=49483139
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JOP/2013/0115A JO3524B1 (en) | 2012-04-23 | 2013-04-23 | Injectable preparation |
Country Status (32)
| Country | Link |
|---|---|
| US (4) | US20150086632A1 (en) |
| EP (1) | EP2868318B2 (en) |
| JP (1) | JP6249944B2 (en) |
| KR (1) | KR102168263B1 (en) |
| CN (4) | CN110638752A (en) |
| AR (1) | AR090775A1 (en) |
| AU (1) | AU2013253518B2 (en) |
| BR (1) | BR112014026398B1 (en) |
| CA (1) | CA2871398C (en) |
| CO (1) | CO7151499A2 (en) |
| CY (1) | CY1123195T1 (en) |
| DK (1) | DK2868318T4 (en) |
| EA (1) | EA026124B1 (en) |
| ES (1) | ES2727454T5 (en) |
| HK (1) | HK1205678A1 (en) |
| HR (1) | HRP20190841T4 (en) |
| HU (1) | HUE043686T2 (en) |
| IL (1) | IL235211A0 (en) |
| IN (1) | IN2014DN08870A (en) |
| JO (1) | JO3524B1 (en) |
| LT (1) | LT2868318T (en) |
| MX (1) | MX361722B (en) |
| MY (1) | MY169099A (en) |
| NZ (1) | NZ630255A (en) |
| PH (1) | PH12014502366B1 (en) |
| PL (1) | PL2868318T5 (en) |
| PT (1) | PT2868318T (en) |
| SG (2) | SG11201406775UA (en) |
| SI (1) | SI2868318T2 (en) |
| TW (1) | TWI641395B (en) |
| UA (1) | UA118084C2 (en) |
| WO (1) | WO2013161830A1 (en) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI562991B (en) | 2012-04-23 | 2016-12-21 | Otsuka Pharma Co Ltd | Dihydrate of benzothiophene compound or of a salt thereof, and process for producing the same |
| JOP20200109A1 (en) | 2012-04-23 | 2017-06-16 | Otsuka Pharma Co Ltd | Injectable preparation |
| JOP20210047A1 (en) * | 2012-10-25 | 2017-06-16 | Otsuka Pharma Co Ltd | Prophylactic and/or therapeutic agent for behavioral and psychological symptoms associated with neurodegenerative disease or impulsive symptoms associated with mental disease containing brexpiprazole or salt thereof |
| WO2017106641A1 (en) * | 2015-12-17 | 2017-06-22 | Assia Chemical Industries Ltd. | Solid state forms of brexpiprazole |
| US10501450B2 (en) | 2016-02-01 | 2019-12-10 | Hexal Ag | Anhydrate-free polymorphically pure micronized crystalline brexpiprazole di-hydrate for use in intramuscular injectable sustained release formulations |
| WO2017208251A1 (en) * | 2016-05-31 | 2017-12-07 | Cipla Limited | A new stable polymorph of brexpiprazole and process for preparation thereof |
| US20200093821A1 (en) | 2016-08-16 | 2020-03-26 | Hexal Ag | Pharmaceutical Compositions of a Benzothiophene Compound |
| EP3577111A1 (en) * | 2017-02-02 | 2019-12-11 | Hexal Aktiengesellschaft | Crystalline brexpiprazole |
| WO2021029020A1 (en) * | 2019-08-13 | 2021-02-18 | 大塚製薬株式会社 | Oral pharmaceutical composition |
| WO2023036003A1 (en) | 2021-09-07 | 2023-03-16 | 四川科伦药物研究院有限公司 | Long-acting brexpiprazole preparation for injection and preparation method therefor |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3402195B2 (en) * | 1997-05-14 | 2003-04-28 | 千寿製薬株式会社 | Aqueous suspension with good redispersibility |
| CA2289618A1 (en) | 1997-05-14 | 1998-11-19 | Shin-Ichi Yasueda | Aqueous suspension preparations with excellent redispersibility |
| US6656505B2 (en) * | 2000-07-21 | 2003-12-02 | Alpharma Uspd Inc. | Method for forming an aqueous flocculated suspension |
| AU2001278779A1 (en) † | 2000-08-25 | 2002-03-04 | Senju Pharmaceutical Co. Ltd. | Aqueous suspension preparations |
| AR033485A1 (en) * | 2001-09-25 | 2003-12-26 | Otsuka Pharma Co Ltd | MEDICINAL SUBSTANCE OF ARIPIPRAZOL OF LOW HYGROSCOPICITY AND PROCESS FOR THE PREPARATION OF THE SAME |
| US20050032811A1 (en) * | 2003-08-06 | 2005-02-10 | Josiah Brown | Methods for administering aripiprazole |
| ES2315721T5 (en) * | 2003-10-23 | 2012-08-24 | Otsuka Pharmaceutical Co., Ltd. | Formulation of sterile controlled-release injectable aripiprazole and procedure |
| TWI320783B (en) * | 2005-04-14 | 2010-02-21 | Otsuka Pharma Co Ltd | Heterocyclic compound |
| JP4315393B2 (en) * | 2005-04-14 | 2009-08-19 | 大塚製薬株式会社 | Heterocyclic compounds |
| EP1933814A2 (en) | 2005-09-15 | 2008-06-25 | Elan Pharma International Limited | Nanoparticulate aripiprazole formulations |
| TW200808375A (en) * | 2006-05-12 | 2008-02-16 | Otsuka Pharma Co Ltd | Hydrogel suspension and manufacturing process thereof |
| TWI415629B (en) | 2006-10-26 | 2013-11-21 | Otsuka Pharma Co Ltd | Aqueous pharmaceutical suspensions containing rebamipide and manufacturing process thereof |
| UA97286C2 (en) * | 2007-07-31 | 2012-01-25 | Оцука Фармасьютикал Ко., Лтд. | Method for producing an aripiprazole suspension and freeze-dried formulation |
| RU2481842C2 (en) * | 2008-03-11 | 2013-05-20 | Алькон Рисерч, Лтд. | Low-viscous highly flocculated triamcinolone acetonide suspensions for intravitreal injections |
| CA2743551C (en) * | 2008-11-19 | 2017-08-15 | Merial Limited | Formulations comprising ceftiofur and ketoprofen or ceftiofur and benzyl alcohol |
| MY174552A (en) * | 2010-08-24 | 2020-04-24 | Otsuka Pharma Co Ltd | Suspension and cake composition containing carbostyryl derivative and silicone oil and/or silicone oil derivative |
| JP5893616B2 (en) * | 2010-10-18 | 2016-03-23 | 大日本住友製薬株式会社 | Sustained release formulation for injection |
| RU2627469C2 (en) * | 2011-03-18 | 2017-08-08 | Алкермес Фарма Айэленд Лимитед | Pharmaceutical compositions comprising water-insoluble antipsychotic agent and sorbitan esters |
| JP2012232958A (en) | 2011-05-09 | 2012-11-29 | Otsuka Pharmaceut Co Ltd | Injection preparation |
| CA2867137C (en) * | 2012-03-19 | 2020-12-08 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions comprising aripiprazole prodrugs and benzyl alcohol |
| JOP20200109A1 (en) | 2012-04-23 | 2017-06-16 | Otsuka Pharma Co Ltd | Injectable preparation |
| TWI562991B (en) * | 2012-04-23 | 2016-12-21 | Otsuka Pharma Co Ltd | Dihydrate of benzothiophene compound or of a salt thereof, and process for producing the same |
-
2013
- 2013-04-22 AR ARP130101320A patent/AR090775A1/en not_active Application Discontinuation
- 2013-04-23 SG SG11201406775UA patent/SG11201406775UA/en unknown
- 2013-04-23 AU AU2013253518A patent/AU2013253518B2/en active Active
- 2013-04-23 TW TW102114433A patent/TWI641395B/en active
- 2013-04-23 EP EP13781458.8A patent/EP2868318B2/en active Active
- 2013-04-23 PT PT13781458T patent/PT2868318T/en unknown
- 2013-04-23 CN CN201911077087.1A patent/CN110638752A/en active Pending
- 2013-04-23 SG SG10201608684QA patent/SG10201608684QA/en unknown
- 2013-04-23 KR KR1020147032097A patent/KR102168263B1/en active IP Right Grant
- 2013-04-23 NZ NZ630255A patent/NZ630255A/en unknown
- 2013-04-23 JP JP2014512621A patent/JP6249944B2/en active Active
- 2013-04-23 PL PL13781458T patent/PL2868318T5/en unknown
- 2013-04-23 CA CA2871398A patent/CA2871398C/en active Active
- 2013-04-23 WO PCT/JP2013/061950 patent/WO2013161830A1/en active Application Filing
- 2013-04-23 JO JOP/2013/0115A patent/JO3524B1/en active
- 2013-04-23 HU HUE13781458A patent/HUE043686T2/en unknown
- 2013-04-23 BR BR112014026398-1A patent/BR112014026398B1/en active IP Right Grant
- 2013-04-23 US US14/395,681 patent/US20150086632A1/en not_active Abandoned
- 2013-04-23 CN CN201710701596.1A patent/CN107536802A/en active Pending
- 2013-04-23 ES ES13781458T patent/ES2727454T5/en active Active
- 2013-04-23 CN CN201380021612.2A patent/CN104363912A/en active Pending
- 2013-04-23 UA UAA201412554A patent/UA118084C2/en unknown
- 2013-04-23 DK DK13781458.8T patent/DK2868318T4/en active
- 2013-04-23 MY MYPI2014703102A patent/MY169099A/en unknown
- 2013-04-23 IN IN8870DEN2014 patent/IN2014DN08870A/en unknown
- 2013-04-23 LT LTEP13781458.8T patent/LT2868318T/en unknown
- 2013-04-23 CN CN202010921162.4A patent/CN111888329A/en active Pending
- 2013-04-23 MX MX2014012734A patent/MX361722B/en active IP Right Grant
- 2013-04-23 EA EA201491937A patent/EA026124B1/en not_active IP Right Cessation
- 2013-04-23 SI SI201331442T patent/SI2868318T2/en unknown
-
2014
- 2014-10-20 IL IL235211A patent/IL235211A0/en active IP Right Grant
- 2014-10-22 PH PH12014502366A patent/PH12014502366B1/en unknown
- 2014-11-21 CO CO14255947A patent/CO7151499A2/en unknown
-
2015
- 2015-06-29 HK HK15106178.4A patent/HK1205678A1/en unknown
-
2017
- 2017-09-12 US US15/702,361 patent/US10624889B2/en active Active
-
2019
- 2019-05-07 HR HRP20190841TT patent/HRP20190841T4/en unknown
- 2019-06-06 CY CY20191100602T patent/CY1123195T1/en unknown
-
2020
- 2020-01-28 US US16/775,222 patent/US20200163960A1/en not_active Abandoned
-
2022
- 2022-02-11 US US17/650,822 patent/US20220305007A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JO3524B1 (en) | Injectable preparation | |
| MX2013011086A (en) | (alpha- substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5 -triazinyl benzimidazoles, pharmaceutical compositions containing them, and these compounds for use in treating proliferative diseases. | |
| TR201904614T4 (en) | Novel pyrazole derivative. | |
| PH12016500420A1 (en) | Pharmaceutical composition comprising olmesartan medoxomil and rosuvastatin or its salt | |
| PH12015502539B1 (en) | Cenicriviroc compositions and methods of making and using the same | |
| EA201590805A1 (en) | COMPOSITION WITH IMMEDIATE AND PROLONGED DELIVERY | |
| PH12019501937A1 (en) | Crystalline forms of a 4-pyrimidinesulfamide derivative aprocitentan | |
| BR112015000229A2 (en) | stable aqueous formulations of etanercept | |
| BR112014015568A2 (en) | phenyl carbamate compounds for use in the prevention or treatment of epilepsy | |
| MX2017004772A (en) | Compositions and methods for physiological delivery using cannabidiol. | |
| MX344846B (en) | Combination of active loaded granules with additional actives. | |
| MX2016001422A (en) | Pharmaceutical compositions of fingolimod. | |
| MX2017013636A (en) | Tamper-resistant fixed dose combination providing fast release of two drugs from different particles. | |
| EP2871187A4 (en) | Novel compound or pharmaceutically acceptable salt thereof, and pharmaceutical composition containing same as active ingredient | |
| EP2886112A4 (en) | Composition for preventing or treating eye diseases, containing s-allyl-l-cysteine as active ingredient, and pharmaceutical formulation containing same | |
| MX2017013633A (en) | Tamper-resistant fixed dose combination providing fast release of two drugs from particles. | |
| EP2862573A4 (en) | Composition for treating or preventing diseases caused by vascular permeability, containing imatinib or pharmaceutically acceptable salt thereof as active ingredient | |
| HK1216253A1 (en) | Novel compound, pharmaceutically acceptable salt or optical isomer thereof, method for preparing same, and pharmaceutical composition for prevention or treatment of viral diseases containing same as active ingredient | |
| EA201500366A1 (en) | APPLICATION OF 1-ADAMANTYLETYLOXY-3-MORFOLINO-2-PROPANOL OR ITS PHARMACEUTICALLY ADOPTABLE SALTS IN PHARMACEUTICAL COMPOSITIONS AS A NEURORTHINOPROTECTOR | |
| EA201491477A1 (en) | PHARMACEUTICAL COMPOSITIONS CONTAINING FLUPIRTIN | |
| IN2014DN10683A (en) | ||
| IN2014DE00700A (en) | ||
| TR201105424A2 (en) | A pharmaceutical formulation with zinc active ingredient. | |
| IN2013CH01615A (en) | ||
| GR1007907B (en) | Pharmaceutical composition containing a phenocarbamate acetylcholinesterase inhibitor |